Articles

Patients with Atrial Fibrillation Find Relief with Rivaroxaban

(Pub. 2nd November 2012)   Rivaroxaban is an oral anticoagulant also known as Xarelto. Rivaroxaban is FDA approved to prevent stroke in people with abnormal heart rhythm, and ...

Read More

The Potential of Canagliflozin for the Treatment of Type 2 Diabetes

(Pub. 15th November 2012) Canagliflozin, is a unique inhibitor of sodium glucose co-transporter 2, and looks to be a promising novel treatment for adults with type 2 diabetes in the ...

Read More

Tofacitinib is a Viable Treatment for Ulcerative Colitis

(Pub. 21st August,2012) Tofacitinib is in the news as of late, causing quite a stir in the pharmaceutical arena. Pfizer’s prediction of an FDA approval for this blockbuster ...

Read More

Regorafenib Approved to Treat Metastatic Colorectal Cancer

(Pub. 11th November 2012) On May 23, 2012 Bayer HealthCare announced their submission for approval of a potential blockbuster cancer drug - Regorafenib.  Only several months later ...

Read More

Trelagliptin Succinate - A Once-a-Week Treatment for Type 2 Diabetes - Coming Soon !

(Pub. 1st November 2012) Cases of Diabetes, particularly type 2 Diabetes, have skyrocketed worldwide. According to researchers at the Hebrew University of Jerusalem in Israel, an ...

Read More

The Possibility of an Oral Insulin Treatment for Type 1 and Type 2 Diabetes is Near

(Pub. 27th August 2012) Keeping blood sugar under control is a lifelong commitment for patients with both type 1 and type 2 diabetes. Patients who require insulin to keep their blood ...

Read More

Tofacitinib is a Viable Treatment for Ulcerative Colitis

(Pub. 21st August,2012) Tofacitinib is in the news as of late, causing quite a stir in the pharmaceutical arena. Pfizer’s prediction of an FDA approval for this blockbuster ...

Read More

Liraglutide Is an Efficacious Treatment for Type 2 Diabetes

(Pub. 21st August, 2012)   On January 25, 2010, the FDA approved Liraglutide, a glucagon-like-peptide-1 (GLP-1) receptor agonist, designed to be taken once daily to improve ...

Read More

Is Approval of Apixaban in the U.S. Near?

(Pub. 19th August, 2012) Exciting news emerged at the 2012 International Stroke Conference, which was held in New Orleans in February of 2012. Apixaban was praised by the ...

Read More

Pregabalin Sets the Standard for Effectual, Quick and Tolerable Pain Relief

(Pub. 13th August, 2012) Patients suffering from fibromyalgia, diabetic nerve pain, and pain caused by shingles will find optimum pain relief from Pregabalin.  As the only ...

Read More

Life Extending Lenalidomide is a Viable Treatment Option

(Pub. 19th July, 2012) Lenalidomide is a life extending drug for patients suffering from myelodysplastic syndrome and multiple myeloma. For people with myelodysplastic syndrome, ...

Read More

Rituximab Takes the Lead in Cancer Treatment

(Pub. 15th July, 2012)   Rituximab is in the group of medications known as monoclonal antibodies, which are designed to recognize certain proteins found on the surface of some ...

Read More

Sitagliptin Phosphate Set to Soar in Sales

(Pub. 11th July, 2012) Sitagliptin Phosphate, also known as Januvia, was recently touted as a future   billion dollar boon for the pharmaceutical industry. On June 26, 2012 ...

Read More

Trastuzumab Continues to be Successful for HER2 Breast Cancer Patients

(Pub. 3rd July, 2012) Approximately 15 to 25 percent of breast cancers are documented as an overexpression of the HER2 protein or an amplification of the HER2 gene. As a monoclonal ...

Read More

Benefits of Crizotinib for Adult and Pediatric Cancer Patients

(Pub. 4th July, 2012) Non-small cell lung cancer rates are rising every year. According to the American Cancer Society the rate for men in the U.S. to develop this often deadly disease ...

Read More

 

Dun and Bradstreet